Lincomycin Injectable (iv/im) Generics - Manufacturers & Suppliers
Lincocin (US & EU)
| Product/Composition:- | Lincomycin Injectable (IV/IM) |
|---|---|
| Strength:- | 600 mg/2 mL, 1 g/2 mL, 2 g/2 mL |
| Form:- | Injectable (IV/IM) |
| Reference Brands:- | Lincocin (US & EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Lincomycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, causing bacterial cell death. It is effective against serious Gram-positive infections, including skin and bone abscesses. Benefits include rapid bacterial eradication, high efficacy against resistant strains, and suitability for severe infections when administered properly in hospital settings.
Lincomycin injectable is approved in the EU and US for severe bacterial infections, including skin, soft tissue, and bone infections. In the EU, brands like Lincocin are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic options are available. Both regions require detailed dossiers, including clinical trial results, manufacturing practices, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert regulatory support, dossier preparation, and compliance, visit PharmaTradz. We support seamless market access for lincomycin injectable formulations, adhering to European and US standards for safe, effective antimicrobial therapy.